Identifying the target of a therapeutic compound is key to gaining deeper insights into its mechanism of action and potential toxicities. By applying Limited Proteolysis Mass Spectrometry (LiP-MS ), our Drug Target Deconvolution service offers a unique way to optimize and de-risk your drug discovery journey.
LiP-MS is a novel, label-free approach to identifying on- and off-target binding effects throughout the proteome. It is the only tool to probe protein structural alterations on a proteome scale with peptide-level resolution. As a result, the Drug Target Deconvolution service offers a proteome coverage of up to 9000 proteins in human cells and a high depth of target ID.
The study report will provide you with ranked protein target candidates for rapid target deconvolution and streamlined target validation.
Biognosys is the sole, exclusive provider of proteomics solutions based on the patented LiP-MS technology developed in collaboration with the group of Prof. Paola Picotti at ETH Zurich.
“We had previously enlisted other methods for target deconvolution and validation for our molecular glue program at the global protein structural readout level, including small molecule selectivity in cells. Biognosys’ TrueTargetTM (LiP-MS) platform provided a proteome-wide picture of our glue with peptide-level resolution. Analogous to HDX-MS on recombinant proteins, TrueTarget™ (LiP-MS) simultaneously provided information about conformational changes and small molecule binding sites in cells within one experiment. With Biognosys’ high-quality data and bioinformatics support, we could draw conclusions about endogenous target binding and compound selectivity, moving our program forward with high confidence.”
Maria Stella Ritorto, PhD
Director of Proteomics at Nested Therapeutics, Cambridge, MA
“The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.”
Laboratory Manager, Bayer
Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable [...]
Marie-Therese Mackmull et al. Nature Communications. This publication on Nature Structural and Molecular Biology is the result of the collaboration betwee [...]
Hendricks et al. American Chemical Society's Chemical Biology Journal. The publication shows how orthogonal proteomics approaches can be applied to quanti [...]
Cappelletti V et al. Cell In this study, an ETH Zurich team led by Biognosys’ scientific advisor and inventor of the LiP-MS technology, Paola Picotti, h [...]
Piazza I et al. Nature Communications. Chemoproteomics enables protein target identification of bioactive compounds, unraveling the mode of action of drug [...]
Slide Deck from Minisymposium #21 at AACR 2021 Presenter: Nigel Beaton A collaboration with: AstraZeneca, ETH Zurich Minisympos [...]
The results are presented and discussed with you in a seminar or webinar and delivered electronically in PDF and Excel formats that contain:
Dose response curves for LiP peptides from protein candidates
a) Protein target candidates ranked by aggregate LiP score
b) Compound affinity concentration for each protein candidate
c) Mapping of regulated peptides of top 3 candidates on protein tertiary structures, if available
Drug Target Deconvolution is applicable to complex biological matrices, including a wide variety of cell lines and organisms.
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.